Why Buying a Purpose-built Software Platform for Expanded Access Program Management is the Superior Choice for Pharmaceutical Companies

Managing Expanded Access Programs (EAPs) allows patients with life-threatening conditions to access investigational therapies, but doing so requires navigating complex regulatory, operational, and data management challenges. Pharmaceutical companies, from large enterprises to small and mid-sized biotechs, must decide between building a custom solution in-house or buying a vendor-developed platform.